A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

NCT02400775 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Essential Hypertension With Stable Angina and Dyslipidemia

Interventions

DRUG: Azilsartan

Sponsor

Takeda